Greenwich LifeSciences News

12 Health Care Stocks Moving In Monday's After-Market Session

GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to

BenzingaApr 22 16:31 ET

Insiders Are Piling Into These 10 Healthcare Stocks in 2024

Yahoo FinanceApr 10 15:30 ET

Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$57,240 in Common Stock

$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 3,000 shares of Common Stock on Apr 1, 2024 at an average price of $19.08 for a total value of $57,240.Source: Announcement Wha

moomoo NewsApr 3 06:50 ET

Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$49,950 in Common Stocks

$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 2,500 shares of Common Stocks on Mar 22, 2024 at an average price of $19.98 for a total value of $49,950.Source: Announcement W

moomoo NewsMar 26 06:47 ET

Insiders Buying Greenwich LifeSciences And 2 Other Stocks

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t

BenzingaMar 25 09:00 ET

Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$26,520 in Common Stocks

$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 1,500 shares of Common Stocks on Mar 20, 2024 at an average price of $17.68 for a total value of $26,520.Source: Announcement W

moomoo NewsMar 22 06:45 ET

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

GlobeNewswireMar 13 06:00 ET

Insiders Continue to Buy Greenwich LifeSciences, Inc. (NASDAQ:GLSI) and Now Own 55% Shares

Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable ownership The top 4 shareholders own 52% of the company Insiders have bought re

Simply Wall StMar 12 07:21 ET

Greenwich LifeSciences Partners With GEICAM in Spain & Conducts First Site Initiation Visits in Europe

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

GlobeNewswireMar 12 06:00 ET

(SEC Amendment) Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$43,715 in Common Stocks

$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 3,500 shares of Common Stocks on Mar 5, 2024 at an average price of $12.49 for a total value of $43,715.Source: Announcement Wh

moomoo NewsMar 7 10:23 ET

Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing

Snehal Patel, 10% Owner, Director, CEO and CFO, on March 05, 2024, executed a purchase for 30,500 shares in Greenwich Lifesciences (GLSI) for $380,945. Following the Form 4 filing with the SEC, Patel

MT NewswiresMar 7 06:52 ET

Greenwich LifeSciences(GLSI.US) 10% Shareholder Buys US$53,423 in Common Stocks

$Greenwich LifeSciences(GLSI.US)$ 10% Shareholder Patel Snehal purchased 4,100 shares of Common Stocks on Mar 4, 2024 at an average price of $13.03 for a total value of $53,423.Source: Announcement Wh

moomoo NewsMar 6 06:46 ET

HC Wainwright & Co. Reiterates Buy on Greenwich LifeSciences, Maintains $36 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price target.

BenzingaFeb 28 13:23 ET

Expanding Horizons: Bullish Buy Rating as Greenwich LifeSciences's Breast Cancer Trial Goes Pan-European

TipRanksFeb 28 06:27 ET

Greenwich LifeSciences Stock Jumps 8% on Phase 3 Study Expansion

Seeking AlphaFeb 27 10:00 ET

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand Into Five Largest European Countries

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01,

GlobeNewswireFeb 27 06:00 ET

Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe

Greenwich LifeSciences (GLSI) shares were up more than 7% in recent Thursday trading after the company said the European Medicines Agency has approved the expansion of its phase 3 trial evaluating GLS

MT NewswiresFeb 22 11:26 ET

Greenwich Lifesciences Announces Acceptance for Flamingo-01 Trial by EMA

Seeking AlphaFeb 22 07:24 ET

Greenwich LifeSciences Gains EMA Nod for Breast Cancer Prevention Trial Expansion

InvestingFeb 22 06:20 ET

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01,

GlobeNewswireFeb 22 06:00 ET